Skip to content

Use of a Share Decision Making Tool in the Care of Acute Cystitis Without Risk of Complication in Primary Care

Utilisation d'un Outil de décision médicale partagée Dans la Prise en Charge Des Cystites Aigues Sans Risque de Complication en médecine générale : Comparaison de la Consommation d'Antibiotique Entre Deux Groupes randomisés en Cluster.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04272281
Acronym
ARIBO
Enrollment
169
Registered
2020-02-17
Start date
2020-07-22
Completion date
2022-02-17
Last updated
2026-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystitis

Keywords

primary health care, share decision making, antibiotics, daily activities

Brief summary

the aim of this trial is to demonstrate that when caring women with symptoms of acute cystitis without any risk of complication, general practitioner may use share decision making tool to help patients better understand the stakes of taking antibiotics.

Detailed description

Each year, more than 2.000.000 patients visit their general practitioners for a acute cystitis. The scientific literature shows that acute cystitis without risk of complication cause complications, such as pyelonephritis, in a very rare cases. However, French guidelines systematically request an antibiotic therapy as soon as the diagnostic is confirmed with the only goal to lowering symptomatology. Recent studies show that some informed women would like not to take antibiotics and pain-killers could be as effective as antibiotics. Canadian studies assessing share decision making tools in patients with acute respiratory infection have shown that matching antibiotic treatment with the patient values lower such prescription without any impact on clinical outcomes . Investigators aim to assess a similar strategy in patients with acute cystitis. This study will compare a group following French guidelines versus one using a share decision making tool to determine if, after being informed of the benefice and risk of this treatment, patient still want an antibiotic. Targeting instead of systematic prescription will reduce antibiotic consumption. After diagnostic of acute cystitis to a woman between 18 and 65 years, investigators check if they filing all study criteria and ask for authorization to add them to the study. Then they'll act following their group instruction, and get information (antibiotic prescription or not, score to the Activity Impairment Assessment (AIA) scale, Score to satisfaction scale). Then patients will be followed by phone contact on day 5, day 14 and day 90 after inclusion to get information on antibiotic use, AIA and satisfaction scores and clinical outcomes, such urinary infection. Data on antibiotics delivery by pharmacy will be obtained through National assurance database.

Interventions

PROCEDUREmedical shared decision

The experimental group will use the share decision making tool during consultation to adapt antibiotherapy

PROCEDUREStandard medical care

control group will act as usual in their practice.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* woman * between 18 and 65 years * symptom of acute cystitis without risk of complication * affiliated to the French public welfare system * with signed consent

Exclusion criteria

* anomaly of the urinary canal * pregnancy * more than 3 cystitis during the last year * cancer, immunosuppression * hemopathy, fever * back-pain * severe renal failure * refuse to give consent and previously participate to the study * under guardianship

Design outcomes

Primary

MeasureTime frame
Use of antibiotic for acute cystitis without risk of complicationDay 14 after inclusion (day 0)

Secondary

MeasureTime frameDescription
Score at the "Activity Impairment Assessment" scaleDay 0, Day 5 and Day14Scale from 0 (never) to 4 (always) on several items about usuals activities limitations.
Score at the satisfaction scaleDay 0, Day 5, Day14 and Day 90Scale from 0 (not satisfied) to 10 (very satisfied) on satisfation about medical care.
Recurrence of the infectionBetween Day 15 and Day 90Infection reccurence will be assessed with the number of dispensation of antibiotics between day 15 and day 90.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 28, 2026